Clinical Trial Update: Biomarker Study of Acamprosate in Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 biomarker study investigating acamprosate in schizophrenia and schizoaffective disorder; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• acamprosate (acamprosate)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED | Results posted: 2018-01-23